SCHEMBL7548609

SCHEMBL7548609

Cc1ccncc1.OCCNc1cc(-c2ccccn2)nc(-c2ccccn2)c1.[Pt]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR39 O43194 3/20 0.44
TYRO3 Q06418 2/20 0.41
MERTK Q12866 2/20 0.41
CYP3A4 P08684 1/20 0.41
KARS1 Q15046 1/20 0.41
FLT3 P36888 1/20 0.41
GAS6 Q14393 1/20 0.41
CCR1 P32246 2/20 0.41
CCR5 P51681 2/20 0.41
CCR8 P51685 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ADORA3 P0DMS8 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
ALPL P05186 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ALPI P09923 1/20 0.39
ALPG P10696 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7551921 0.88 CCR1 (0.51) GPR39TYRO3MERTKCYP3A4FLT3
SCHEMBL7549045 0.81 CCR1 (0.45) GPR39CYP3A4FLT3CCR1CCR5
SCHEMBL7546447 0.79 KDM4E (0.51) TYRO3MERTKKARS1FLT3GAS6
Terpyridine SCHEMBL7108793 0.77 KDM4E (0.67) FLT3CCR1CCR5CCR8TDP1
SCHEMBL7546716 0.73 CCR1 (0.56) GPR39CYP3A4CCR1CCR5CCR8
SCHEMBL7552134 0.72 CCR1 (0.44) GPR39CYP3A4FLT3CCR1CCR5
Terpyridine SCHEMBL7114340 0.72 KDM4E (0.58) CYP3A4FLT3CCR1CCR5CCR8
SCHEMBL12131388 0.70 CCR1 (0.45) GPR39CYP3A4CCR1CCR5CCR8
SCHEMBL11996129 0.70 CCR1 (0.51) GPR39CCR1CCR5CCR8TDP1
SCHEMBL1104803 0.70 CCR1 (0.64) FLT3CCR1CCR5CCR8TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0885233-B1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION (GB) 2002-06-19 EP disclosed
US-20020013306-A1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION LIMITED (GB) 2002-01-31 US disclosed
EP-1164138-A1 Terpyridine-platinum (II) complexes ISIS INNOVATION LIMITED (GB) 2001-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013306-A1 TERPYRIDINE-PLATINUM(II) COMPLEXES TOP2A, TOP1, TOP2B GPR39 4786/4885TYRO3 4571/4885MERTK 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.